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ABSTRACT
The prevalence and incidence of systemic sclerosis (SSc)
in The Netherlands is unknown. The same holds true for
its leading causes of death: pulmonary fibrosis and
pulmonary arterial hypertension (PAH), for which effective
treatment options have recently become available.
Objective: To establish the prevalence and incidence of
SSc and its pulmonary complications.
Methods: Detailed information on patients in the
POEMAS registry, ‘‘Pulmonary Hypertension Screening, a
Multidisciplinary Approach in Scleroderma’’, consisting of
819 patients, was combined with a nationwide ques-
tionnaire.
Results: By combining the two sources the prevalence of
SSc was found to be 8.9 per 100 000 adults. The
incidence was 0.77 patients per 100 000 per year. PAH
was diagnosed in 9.9% of SSc patients. The prevalence of
interstitial lung disease in SSc varied from 19% to 47%
depending on the definition used.
Conclusion: This study clarifies the epidemiology of SSc
in The Netherlands and confirms the frequent occurrence
of pulmonary complications, based on 654 cases. This can
and will be studied further in the ongoing POEMAS study.
Systemic sclerosis (SSc, scleroderma) is an auto-
immune connective tissue disease characterised by
vascular lesions, induration and thickening of the
skin, and fibrotic changes in other organs, pre-
dominantly in the lungs, heart, intestinal tract,
kidneys, muscles and joints.1 2 The leading cause of
death in SSc is pulmonary involvement consisting
of pulmonary fibrosis with or without pulmonary
hypertension (PH) or pulmonary arterial hyperten-
sion (PAH).3–5 Published estimates of the preva-
lence of SSc vary widely, depending on the
observation period, methods used and geographical
area and it is reported to be from 0.4 to 469 per
100 000 people.2 6–13 Furthermore, the prevalence of
PAH in SSc is unclear, but is estimated to be 8% to
12% in studies based on right-heart catheterisation,
the gold standard for diagnosing PAH.3 14 Several
treatments that successfully delay the process of
PAH, such as epoprostenol,15 trepostinil,16 bosen-
tan,17 18 sitaxentan19 and sildenafil,20 have recently
become available. In addition, two studies have
shown that cyclophosphamide has a significant
although clinically minor effect on pulmonary
fibrosis in SSc patients.5 21 In light of these
treatment possibilities and given the late occur-
rence of symptoms of eventually life-threatening
pulmonary involvement in SSc, screening for both
PAH and pulmonary fibrosis has become a major
goal in scleroderma referral centres.
To date, the optimal screening method for PAH
has not been determined. A combination of
decreased carbon monoxide diffusion capacity
and elevated systolic pulmonary arterial pressure
(PAP) estimated by echocardiography is the
method used in most clinics.3 22 23 A decreased
decreased carbon monoxide diffusion capacity is,
however, also present in other diseases limiting
oxygen uptake and echocardiography is flawed by
both false-positive and false-negative results.
Right-heart catheterisation is the gold standard
for establishing the diagnosis of PAH.24 25 In order
prospectively to investigate the optimal screening
method for PAH in SSc the POEMAS study was
started in 2005. POEMAS, an investigator initiated
study, is a Dutch acronym for ‘‘Pulmonale hyper-
tensie Opsporing Een Multidisciplinaire Aanpak bij
Sclerodermie’’ translated as ‘‘Pulmonary hyperten-
sion screening, a multidisciplinary approach in
scleroderma’’, and intends to establish the optimal
screening method for PAH in SSc. For this purpose,
patients with SSc, without PAH or interstitial lung
disease at inclusion, will prospectively be studied
for 5 years. In order to find eligible patients for the
POEMAS study, all patients with SSc treated in the
participating hospitals were screened and docu-
mented according to our protocol. Their data were
entered into the POEMAS registry.
The objectives of this study are to determine the
point prevalence and incidence of SSc in The
Netherlands and to establish the prevalence of
PAH and interstitial lung disease in the same
population.
PATIENTS AND METHODS
Prevalence of patients with SSc in The Netherlands
In The Netherlands, patients with SSc are referred
by the family practitioner to either rheumatolo-
gists or internists, mostly clinical immunologists.
All rheumatologists and internists use a compu-
terised diagnosis system for all patients, which is
designed to calculate costs for health insurance.
Occasionally, referral is to dermatologists, who in
their turn refer patients with SSc to rheumatolo-
gists. To determine the prevalence and incidence of
SSc and the associated PAH and interstitial lung
disease in The Netherlands, cases were found using
two sources: first, the POEMAS registry, and
second, a nationwide questionnaire among rheu-
matologists and clinical immunologists in The
Netherlands. As a denominator the total popula-
tion in The Netherlands aged 18 years or older on 1
January 2007 was used, as provided by the
Statistics Netherlands registry (www.cbs.nl).
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Fifteen hospitals currently participate in the POEMAS study,
including both academic (n = 5) and non-academic hospitals
(n = 10). All patients 18 years and older referred to these
hospitals and diagnosed with SSc according to the preliminary
classification criteria of the American College of
Rheumatology26 and the LeRoy criteria for early SSc27 in the
period 1 January 1 2005 to 1 August 2007 were included in the
registry. Demographic and clinical characteristics of all patients
were obtained from their clinical records.
To obtain information on the number of patients treated in
other hospitals in The Netherlands, a questionnaire was sent to
all registered rheumatologists and clinical immunologists,
excluding the hospitals participating in the POEMAS study. If
the questionnaire was not returned, a second was sent and the
doctors were personally requested by telephone to return the
survey. In the questionnaire they were asked to provide the
number of all alive SSc patients aged 18 years and older and the
number of SSc patients with PAH, as diagnosed by right-heart
catheterisation, currently treated in their practice. The source of
the information for the questionnaire was the computerised
diagnosis lists available in all Dutch hospitals.
POEMAS study population
Demographic and clinical information on the patients are
shown in table 1. Interstitial lung disease was determined by
pulmonary function tests and high-resolution computer tomo-
graphy (HRCT) scan. For the assessment of signs of interstitial
lung disease on the HRCT scan the same method was used as in
a recent, large idiopathic pulmonary fibrosis trial.5 In short, this
scoring method consists of the evaluation of the HRCT scan at
three levels: the midarch of the aorta, the main carina and 1 cm
above the diaphragm. Both fibrosis and ground glass opacity
(GGO) were graded from 0 to more than 75% of the pulmonary
surface, providing a score between 0 and 5. Left and right lung
scores were averaged, resulting in a total GGO score and a
fibrosis score, both between 0 and 15.28 29 The patients were
divided into two groups: one with HRCT scan scores of 3 or less
for GGO and fibrosis, representing minimal or absent interstitial
pulmonary involvement and another with more extensive
interstitial involvement. Furthermore, all patients were classi-
fied as having a total lung capacity (TLC) of 70% or greater or
less than 70% of predicted.22 30 Systolic PAP was calculated by
applying the simplified Bernoulli equation on maximum
tricuspid regurgitation velocity and adding the estimated right
atrial pressure. Right atrial pressure was estimated using inferior
caval vein diameter and the effects of respiratory variation.31
PAH was suspected when on echocardiography the estimated
systolic PAP was 35 mm Hg or greater at rest in patients
without a history of pulmonary embolism or other possible
causes of PH and with a normal TLC. In all cases with an
elevated systolic PAP on echocardiography right-heart catheter-
isation was performed, and when the mean PAP was greater
than 25 mm Hg at rest with a normal wedge pressure, a
diagnosis of PAH was established.22 25 32
Some patients were registered twice in the database due to
referral to an academic centre or moving house. Those patients
were recognised using date of birth and postal code and the
duplicates were removed.
Statistical analysis
All statistical analyses were performed using SPSS version 14.0.
To calculate the prevalence of SSc, the number of patients from
the POEMAS registry was combined with the results from the
survey. The response to the survey was 70%; thus for
calculations the number of patients not included in the
POEMAS registry was estimated to be 100/70 times the result
of the questionnaires. Adding the POEMAS registry number to
the estimated number in the other hospitals provided the total
number of patients in The Netherlands. To provide an estimate
of the prevalence, this number was divided by the number of
inhabitants aged 18 years or older in The Netherlands. The
percentage of patients in The Netherlands with SSc included in
the POEMAS registry was calculated. To establish the incidence,
the number of new cases in 2005 and 2006 in the POEMAS
database was determined, generalised to the total population,
using the calculated percentage of patients registered in the
POEMAS database, and then divided by the total Dutch
population. For determination of the prevalence of PAH, both
the POEMAS registry and the questionnaires were used. For the
presence of interstitial lung disease, information from the
POEMAS registry was the sole source. The prevalence of the
latter complication was calculated by generalising the POEMAS
registry to the total population in The Netherlands.
Quantitative variables were summarised as median and full
range and were compared using the t test. Groups were
compared using the Mann–Witney U test. All statistical
analyses were two-tailed and p values less than 0.05 were
considered statistically significant.
RESULTS
In the POEMAS registry 654 SSc patients have been included up
to 1 August 2007. Eighty-two and 18% of the patients were
included in the academic and non-academic hospitals, respec-
tively. The study population consisted of 493 (75.4%) women
and 161 (24.6%) men. The median (range) age of the patients
with SSc was 59.1 years (19–90). The median age (range) at
diagnosis of SSc was 50.0 years (3–86). Antinuclear antibodies
were detected in 91.7% of the SSc patients, and the frequency of
other disease-specific autoantibodies as well as the demographic
description of the patients is shown in table 1.
Prevalence of SSc
The response to the questionnaire was 70%. The response rates
of doctors working in academic and non-academic hospitals
were similar. Therefore the questionnaire was considered to be
representative. Through the questionnaire, another 346 SSc
cases were recognised. When combining the results of the
survey and the POEMAS study, the estimated number of SSc
patients in The Netherlands in 2005 and 2006 is 1148. The total
Dutch population aged 18 years and older on 1 January 2007
Table 1 Demographic and autoantibody status of patients evaluated in
the POEMAS study
SSc (n = 654)
Women : men 493 : 161
Age, years (median, range) 59 (19–90)
Age at diagnosis, years (median, range) 50 (3–86)
ANA positive (%) 588 (92%)
ACA positive (%) 191 (30%)
Anti-TOPO positive (%) 139 (22%)
Anti-RNP positive (%) 37 (6%)
TLC >70% of predicted 312/388
HRCT scan minimal or no interstitial lung disease 103/262
ACA anticentromere antibody; ANA, antinuclear antibody; anti-RNP, antiribonuclear
protein antibodies; anti-TOPO, antitopoisomerase antibody; HRCT, high-resolution
computer tomography; SSc, systemic sclerosis; TLC, total lung capacity.
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was 12 793 440. Using this as the denominator population, the
estimated prevalence of SSc is 8.9 per 100 000 inhabitants
(table 2).
Incidence of SSc
In the hospitals participating in the POEMAS study, 58 new SSc
patients were diagnosed in 2005 and 53 in 2006. As 57.0% of the
SSc patients in The Netherlands were calculated to be registered
in the POEMAS study (654/(100/70*346 + 654)*100), the
estimated annual number of new scleroderma patients is 103
in 2005 and 94 in 2006. Generalising this number to the
denominator population, the estimated incidence of SSc in The
Netherlands is 0.77 per 100 000 inhabitants aged 18 years or
older per year (table 2).
Pulmonary hypertension
The presence of PH, either PAH or PH associated with
pulmonary fibrosis, was reported in 11.6% of the SSc patients
in the survey. In the POEMAS registry PH was prevalent in 56
(8.6%) SSc patients. Combining these results, the estimated
prevalence of PH in SSc in The Netherlands is 9.9% (table 2).
SSc patients with PH had a significantly lower TLC compared
with patients without PH, namely 70.5% (35–132%) of
predicted and 91.0% (32–137%) of predicted, respectively
(p,0.01). Also, the median (range) age of patients with SSc
and PH was significantly higher than the patients without PH:
67.2 years (31.6–84.7) versus 58.5 years (19.6–90.0). No differ-
ences regarding PH were found in gender or autoantibodies.
When using a TLC less than 70% of predicted as a diagnosis of
interstitial lung disease, this cohort consisted of 35 (61.4%) PAH
and 22 (38.6%) PH patients.
Interstitial pulmonary disease
Pulmonary function tests were performed in 388 (77.9%) SSc
patients in the last 6 months before registration in the POEMAS
database. The median (range) TLC in SSc was 90.0% (32–152%)
of predicted. Figure 1 shows the TLC values as a percentage of
predicted in SSc patients. The TLC as a percentage of predicted
was 70% or greater in 81.0% of patients. To date, HRCT
scanning has been performed and scored according to the
described protocol in 292 SSc patients. A score of 3 or less for
GGO and fibrosis, representing minimal or absent interstitial
pulmonary involvement, was found in 53.0% of the HRCT
scans of the SSc patients. In SSc patients without pulmonary
involvement according to the HRCT scan, anticentromere
antibodies were present more frequently than in patients with
a GGO or fibrosis score greater than 3 (p,0.01). No differences
were found between patients in the normal and abnormal
HRCT scan groups regarding age, disease duration, other
autoantibodies or sex. The median (range) TLC in patients
with an HRCT scan score of 3 or less was 97.0% (46–137%) of
predicted, which differed significantly from patients with higher
HRCT scan scores, namely 71.5% (35–134%) of predicted
(p = 0.01). When an HRCT scan score of more than 3 is used
to define pulmonary interstitial disease, this complication is
present in 47.0% (139/296) of the patients. If a TLC less than
70% of predicted is used to define interstitial lung disease, this
complication is present in 18.8% (91/485) of the patients. The
HRCT scores correlated significantly with the TLC as a
percentage of predicted, r = 0.527 (p,0.01).
DISCUSSION
This study on the prevalence and incidence of SSc is based on
the largest European population of SSc patients described to
date. We found an estimated prevalence of SSc in The
Table 2 Prevalence and incidence of SSc in The Netherlands, and prevalence of PH with SSc in The
Netherlands
SSc
Survey
(N)
POEMAS
(N)
The Netherlands*
(N)
Prevalence of SSc 346 654 1148 8.9 per 100 000 persons
Proportion of total no of patients 30.0% 57.0% 100%
Incidence of SSc NA 56 98 0.77 per 100 000 persons
Prevalence of PH 40 56 113 9.9% of patients
*The number of patients in The Netherlands was calculated by the addition of the number of patients in the survey (N), generalised
to the whole country (N(survey)/7*10) and the POEMAS cases.
PH, pulmonary hypertension; SSc, systemic sclerosis.
Figure 1 Total lung capacity as a percentage of predicted in systemic
sclerosis.
TLR, total lung capacity.
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Netherlands of 8.9 per 100 000 adult persons based on 1000
cases. This finding is comparable with recent findings in the
United Kingdom, where an estimated prevalence of 8.2 per
100 000 has been published.7 The prevalence in France and
Greece is reported to be 15.8 and 15.4 per 100 000 persons,
respectively,6 10 whereas the prevalence in the United States and
Australia is reported to be higher, 24.2 and 23 per 100 000
persons, respectively.12 33 The differences in prevalence in
different countries can be explained by several factors, such as
the criteria used to diagnose patients, the preliminary classifica-
tion criteria of the American College of Rheumatology26 or the
LeRoy criteria for early SSc,27 or the group size.11 12 Furthermore,
differences in ethnic background may lead to a higher
prevalence of SSc in the United States and Australia.8 12 33 For
the identification of SSc patients in the POEMAS registry we
used both classification criteria,26 27 which allowed us to include
patients with early disease and limited cutaneous involvement
without interstitial lung disease.
The POEMAS study is performed by doctors with a special
interest in SSc and PH. To avoid an overestimation of the
prevalence of SSc, we included a questionnaire to all other
rheumatologists and clinical immunologists in The Netherlands.
The responses are considered to be a reflection of the total
population of The Netherlands. A proportion of patients with
SSc is not yet referred to the rheumatologist but treated only in
primary care or by other specialists such as dermatologists or
vascular surgeons, but in our opinion this is a small minority of
the total number of patients. By combining the results of the
questionnaire and the POEMAS registry we were able to
identify 87% of the SSc patients, and therefore the estimated
prevalence presented in this study is robust.
The incidence of SSc was calculated using only the POEMAS
study population, of which the date of diagnosis is known in
every case. The calculated incidence of 0.77 per 100 000 is
between the reported incidence in the United States (1.9 per
100 000), Greece (1.1 per 100 000) and the United Kingdom (0.4
per 100 000).6 12 34 As our estimated incidence is based on a
study period of only 2 years and the number of incident cases is
somewhat smaller than the US and Greek cohorts, this figure
should be interpreted with care and should be confirmed in the
second part of the POEMAS study, with an observational period
of 5 years.
The prevalence of PH in this study is a combined prevalence
of PAH and PH associated with pulmonary fibrosis. As PH
associated with fibrosis is a hypoxia-driven disease rarely
occurring in SSc, probably all patients with PH in this study
can be categorised as PAH. We found a prevalence of PH in SSc
of 9.9%, which is lower than expected.35–37 This may be that
patients with PH associated with SSc are treated by pulmonol-
ogist or cardiologists, sometimes without recognising the
systemic disease, as can be the case in every country. Another
reason could be that screening for PH by annual echocardio-
graphy has not yet been incorporated into standard care in all
hospitals. In the POEMAS study this will be performed twice a
year, providing us with the opportunity to study further the
prevalence and incidence of PH in the scleroderma spectrum of
diseases.
The POEMAS registry provides detailed information on 654
SSc patients. The percentage of patients with a TLC of 70% or
greater in SSc was 81.2%. The expected percentage of interstitial
lung disease in this connective tissue disease is much higher, but
may differ depending on the definition and methods used.
Earlier studies reported pulmonary fibrosis in 35–53% of SSc
patients.37 Apparently, a TLC of 70% or greater does not exclude
interstitial lung disease. Combining TLC with HRCT scan
findings is, however, expected to be a more sensitive method for
this purpose; the POEMAS study will provide further informa-
tion.
In summary, we have described the epidemiology of SSc in
The Netherlands. Our findings reveal that the prevalence and
incidence of SSc in The Netherlands is similar to the data from
the United Kingdom. The prevalence of PH and interstitial
pulmonary disease is, however, lower than expected. With the
POEMAS study in progress, additional information on epide-
miology, PAH and interstitial lung disease is pending.
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